Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants

被引:59
|
作者
Kampf-Sherf, O
Zlotogorski, Z
Gilboa, A
Speedie, L
Lereya, J
Rosca, P
Shavit, Y
机构
[1] Hebrew Univ Jerusalem, Dept Psychol, IL-91242 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Jerusalem, Israel
[3] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA
[4] Shalvata Psychiat Hlth Ctr, Hod Hasharon, Israel
[5] Talbieh Mental Hlth Ctr, Winnick Clin, Jerusalem, Israel
关键词
serotonin; major depression; neuropsychological assessment; prediction of treatment responsiveness;
D O I
10.1016/j.jad.2004.02.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Only two thirds of patients with major depression (MD) respond to antidepressants. Thus, far applicable predictors of responsiveness to selective serotonergic reuptake inhibitors (SSRIs) have not been found. Cumulative evidence linking serotonergic depletion and cognition led us to hypothesize that the neuropsychological functioning of major depression patients may predict their responsiveness to SSRI antidepressants. Methods: Fifty-five patients meeting DSM-IV criteria for major depression and strict inclusion and exclusion criteria underwent an extensive clinical and neuropsychological assessment prior to the initiation of selective serotonergic treatment. Following 6 weeks of treatment, severity of depression was reassessed, yielding a responsiveness score by which classification of each subject as a responder or nonresponder was made. The study was double blind. Results: Logistic regression yielded neuropsychological indices, which significantly predicted the probability of depressed patients to respond favorably to SSRIs. Responders were characterized by better functioning in "simple" tasks and by worse functioning in "complex" tasks compared to nonresponders. No differences were found for more lateralized right or left hemisphere functions between responders and nonresponders. Limitations: Drug treatment comprised of SSRIs but was not standardized. Responsiveness was assessed following 6 weeks of treatment providing for initial amelioration rather than full remission. Placebo response was not controlled for. These limitations may influence the interpretation of the findings. Conclusions: The present findings suggest that responders and nonresponders to SSRIs might be distinguished by their neuropsychological functioning before treatment. If our findings are replicated, more efficient treatment might be practiced. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 50 条
  • [1] Selective serotonin reuptake inhibitors antidepressants (SSRIs)
    Chavez-Leon, Enrique
    Ontiveros Uribe, Martha Patricia
    Gomez, Carlos Serrano
    SALUD MENTAL, 2008, 31 (04) : 307 - 319
  • [2] Effects of tricyclic antidepressants, selective serotonin reuptake inhibitors, and selective serotonin-norepinephrine reuptake inhibitors on the ocular surface
    Ismayilov, Ayna Sariyeva
    Celikel, Guler
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2023, 86 (05)
  • [3] Depression, selective serotonin reuptake inhibitors and osteoporosis
    Bab I.
    Yirmiya R.
    Current Osteoporosis Reports, 2010, 8 (4) : 185 - 191
  • [4] Enhanced Responsiveness to Selective Serotonin Reuptake Inhibitors during Lactation
    Jury, Nicholas J.
    McCormick, Betsy A.
    Horseman, Nelson D.
    Benoit, Stephen C.
    Gregerson, Karen A.
    PLOS ONE, 2015, 10 (02):
  • [5] Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants
    O'Reardon, JP
    Chopra, MP
    Bergan, A
    Gallop, R
    DeRubeis, RJ
    Crits-Christoph, P
    BIOLOGICAL PSYCHIATRY, 2004, 55 (09) : 957 - 959
  • [6] Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety
    Kronenberg, Sefi
    Frisch, Amos
    Rotberg, Beni
    Carmel, Miri
    Apter, Alan
    Weizman, Abraham
    PHARMACOGENOMICS, 2008, 9 (11) : 1725 - 1736
  • [7] A Bibliometric Analysis of the WoSCC Literature on the Use of Selective Serotonin Reuptake Inhibitors as Antidepressants
    Li, Jiyang
    Fei, Xinxing
    Wang, Shiqi
    Xu, Zhangyu
    Xu, Fangyuan
    Wang, Jianxiong
    Gao, Yaqian
    Hu, Yue
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4961 - 4974
  • [8] Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants use in hot flashes in oncology
    Elek, T
    Reich, M
    REVUE DE MEDECINE INTERNE, 2004, 25 (03): : 217 - 224
  • [9] Combination therapy with reboxetinefor major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors
    Rubio, G
    San, L
    García-García, P
    Alamo, C
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2003, 31 (06): : 315 - 324
  • [10] Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder
    Bakish, D
    Cavazzoni, P
    Chudzik, J
    Ravindran, A
    Hrdina, PD
    BIOLOGICAL PSYCHIATRY, 1997, 41 (02) : 184 - 190